



# GEORGIA LIFE SCIENCES SUMMIT® 2005

*The Future of Biomedicine*

## CONFERENCE PROGRAM

7:00 AM	REGISTRATION
8:00 AM	WELCOME <b>William D. Johnston, PhD</b> ; President and CEO, Inhibitex, Inc.
8:10 AM	STATE OF THE LIFE SCIENCES INDUSTRY IN GEORGIA <b>Russell M. Medford, MD, PhD</b> ; President and CEO, AtheroGenics, Inc.
8:30 AM	THE CONVERGENCE OF BIOTECHNOLOGY, NANOTECHNOLOGY AND ADVANCED COMPUTING: FORGING NEW VISTAS IN HEALTH, ENVIRONMENTAL MANAGEMENT AND NATIONAL SECURITY <b>George Poste, PhD, DVM</b> ; Director, The Biodesign Institute at Arizona State University and Del E. Webb Distinguished Professor of Biology
9:15 AM	PERSPECTIVES ON THE FUTURE OF BIOMEDICINE <b>C. Thomas Caskey, MD, FACP</b> ; Managing Director, Cogene Ventures
10:00 AM	EXHIBIT AND POSTER VIEWING / REFRESHMENTS
10:30 AM	CONCURRENT FOCUS SESSION I <i>Ia. Personalized Medicine Promises to Advance Health Care</i> <i>Ib. Georgia Public Companies are Capturing World Attention</i> <i>Ic. Regulation and Reimbursement of Modern Medicines</i>
11:45 AM	LUNCH
12:45 PM	WHY BIOTECHNOLOGY NEEDS WORLD CLASS ADVOCACY <b>James C. Greenwood</b> ; President and CEO, Biotechnology Industry Organization (BIO)
1:25 PM	EXHIBIT AND POSTER VIEWING
1:45 PM	CONCURRENT FOCUS SESSION II <i>Ila. Creating a Robust Strategy for Biodefense</i> <i>Iib. Georgia's Next Generation of World-Class Public Companies</i> <i>Iic. The Valuation Squeeze – is Biotech's Financial Model Broken?</i> <i>Iid. How Georgia's Research Institutions are Pioneering the Life Sciences</i>
3:00 PM	EXHIBIT AND POSTER VIEWING / REFRESHMENTS
3:15 PM	RESEARCH ADVANCES IN GEORGIA <ul style="list-style-type: none"><li>• <i>Renowned Scientific Speakers</i></li><li>• <i>Poster Session</i></li><li>• <i>Poster Discussions</i></li></ul>
5:20 PM	CLOSING REMARKS <b>Charles S. Craig</b> ; President, Georgia Biomedical Partnership
5:30 PM	GALA PARTY New for 2005 - "Getting to know our Life Sciences Community" Join your colleagues for a night of fun, games and music. Try your skills at the casino table, enjoy the magic of the roaming Zolas and dance to your favorite music spun by Dave Henderson of Jammin' DJs.

## CONCURRENT FOCUS SESSION I (10:30 AM – 11:45 AM)

### Ia. PERSONALIZED MEDICINE PROMISES TO ADVANCE HEALTH CARE

The sequencing of the human genome has opened the door for physicians and pharmaceutical companies to design highly customized treatments that are as unique as each individual patient. Our panel of scientific and policy experts will discuss the impact of Personalized Medicine on: (i) The drug discovery and approval processes. (Is this the end of the blockbuster?); (ii) Integration of diagnostics into drug regimens. (Is there an Amphipip in your doctor's office?); and (iii) The ethics and confidentiality issues of genotypically isolating patient groups. (Are you at risk for heart disease? Who should know?)

**Fred D. Ledley, MD – Moderator;** Professor and Chair, Bentley College

#### *Breakthrough Life Sciences Tools Enable the Realization of Personalized Medicine*

**Peter Dansky;** Vice President/General Manager, Core PCR/DNA Synthesis, Applied Biosystems

#### *What Role Does Government and Public Policy Play*

**Edward Abrahams, PhD;** Executive Director, Personalized Medicine Coalition

#### *An Investor's Perspective*

**Christopher W. Kersey, MD, MBA;** Managing Director, Cogene Ventures

---

### Ib. GEORGIA PUBLIC COMPANIES ARE CAPTURING WORLD ATTENTION

**Robert J. Gould – Moderator;** Vice President Licensing and External Research, Merck & Co., Inc.

**William D. Johnston, PhD;** President and CEO, Inhibitex, Inc.

**Russell M. Medford, MD, PhD;** President and CEO, AtheroGenics, Inc.

**Michael K. Steele;** Vice President, Business Development, Corautus Genetics Inc.

---

### Ic. REGULATION AND REIMBURSEMENT OF MODERN MEDICINES

This Session considers the new and changing FDA environment for clinical trials that will potentially change development timelines, number of patients, and costs of trials. Also the Panel will consider key issues surrounding technology transfer and commercialization as trials move towards approval and the “do’s and don’ts” of manufacturing site selection related to FDA approval and provide insights into device development programs that would maximize the likelihood of early CMS reimbursement.

**Dan Myers – Moderator;** President and CEO, Alimera Sciences, Inc.

#### *A New and Changing FDA Environment for Clinical Trials that will Potentially Change Development Timelines, Number of Patients, and Costs of Trials*

**Robert C. Coleman;** National Drug Expert Investigator, U.S. Food and Drug Administration

#### *Insights into Device Development Programs that would Maximize the Possibility of Timely CMS Reimbursement*

**Karen A. Coleman;** National Expert in Medical Devices, U.S. Food and Drug Administration

#### *Key Issues Surrounding Technology Transfer and Commercialization as Trials Move Towards Approval and the Critical Considerations When Selecting a Manufacturing Partner*

**Robert L. Lewis;** President, IHL Consulting Group, Inc.

## CONCURRENT FOCUS SESSION II (1:45 PM – 3:00 PM)

### IIa. CREATING A ROBUST STRATEGY FOR BIODEFENSE

Recent world events have highlighted the global need for an integrated and robust biological threats strategy. Government requirements for biodefense products present unique opportunities for the development of new technologies and companies. Experts will examine the nature of biological threats, laboratory and surveillance capacity to protect the nation, emergency response strategies, and implications for companies preparing to address biological threats in their business plans. Questions we will use to shape the panel dialogue include: Where are we now; are we better prepared in 2005 than we were in 2000 - if so, for what; is it ever possible to “be prepared?”; what is the level of investment to make it realistic; how important is technology in biodefense; sensor technology - how do we balance cost of specificity versus the cost of false positives; have the organisms of concern changed; is our approach to bioterrorism the correct one; do we prepare for what we have seen versus those that we have not seen?

**C. Michael Cassidy – Moderator;** President and CEO, Georgia Research Alliance (GRA)

**George Poste, PhD, DVM;** Director, The Biodesign Institute at Arizona State University and Del E. Webb Distinguished Professor of Biology

**Daniel M. Sosin, MD, MPH;** Associate Director for Science, Coordinating Office for Terrorism Preparedness and Emergency Response, Centers for Disease Control and Prevention

**Mimi Healy, PhD;** President and CEO, Bacterial Barcodes, Inc.

**Gregory Milman, PhD;** Director, Office for Innovation and Special Programs Division of Extramural Activities National Institute of Allergy and Infectious Diseases

---

### IIb. GEORGIA'S NEXT GENERATION OF WORLD-CLASS PUBLIC COMPANIES

Georgia now has a number of exciting, high-profile publicly traded life science companies. What are the emerging private companies with the technology, management, and financing to take the next step? We will showcase a number of Georgia private companies that are already players on the national stage and represent potential public leaders of the future.

**John P. Richard, MBA – Moderator;** General Partner, Georgia Venture Partners

**Dan Myers;** President and CEO, Alimera Sciences, Inc.

**Eric Tomlinson, PhD, DSc;** President and CEO, Altea Therapeutics

**David Stern;** President and CEO, CardioMEMS, Inc.

---

### IIc. THE VALUATION SQUEEZE — IS BIOTECH'S FINANCIAL MODEL BROKEN?

With a few exceptions, the valuations of the more than 40 biotechnology companies that went public during the last 24 months were lower than they were during the “window” of 2000, despite the vast majority of these companies being, on average, more mature, better capitalized and much further down the clinical development curve. Further, many more initial public offerings have recently been postponed due to “poor market conditions”. Accordingly, the returns, if any, which venture capital funds and institutional investors are generating on late stage biotechnology are lower than anticipated.

Why are public market valuations for biotechnology companies so hard to come by? More importantly, are these lower valuations, and the returns they offer, sufficient to continue to attract institutional investors, venture capital, other investors and talented management teams to the biotechnology sector? Is biotechnology's financial model broken? If so, what does it signify for the future of biotechnology?

**Russell H. Plumb, MBA – Moderator;** Vice President, Finance and Administration, Chief Financial Officer, Inhibitex, Inc.

**E. James Streator III;** Head of Healthcare Investment Banking, Susquehanna Financial Group, LLP

**Michael A. Henos, MBA;** Managing General Partner, Alliance Technology Ventures LP

**Stephen R. Biggar, MD, PhD;** Principal, Baker Brothers Investments

## **II.d. HOW GEORGIA'S RESEARCH INSTITUTIONS ARE PIONEERING THE LIFE SCIENCES**

This session provides a unique opportunity to hear senior leaders from Georgia's top research universities. The panel will address their respective institutional efforts to facilitate the commercialization of life science technologies. Topics include major research initiatives, technology transfer, and bio-incubation. In addition, the panel will address other areas of concern including conflict of interest, consulting, and indirect cost rates.

**Todd T. Sherer, PhD – Moderator;** Assistant Vice President for Research and Director of the Office of Technology Transfer, Emory University

**Frank G. Stout, MPH;** Vice President for Research Administration, Emory University

**Charles D. Derby, PhD;** Associate Dean for Natural and Physical Sciences, Georgia State University

**Charles L. Liotta, PhD;** Vice Provost for Research and Dean of Graduate Studies, Georgia Institute of Technology

**Barry D. Goldstein, PhD;** Provost and Chief Academic Officer, Medical College of Georgia

**David Lee, PhD;** Vice President of Research and Associate Provost, University of Georgia

---

## **RESEARCH ADVANCES IN GEORGIA (3:15 PM – 5:15 PM)**

Distinguished scientists from Georgia academe and industry will describe their critical findings / endeavors in several short talks designed for the general audience.

**Martin A. Wasserman, PhD – Moderator;** Senior Vice President of Discovery Research and Chief Scientific Officer, AtheroGenics, Inc.

### **1. SPEAKER SESSION**

#### ***A Holistic Approach to Complex Diseases: Genomics, Proteomics and Immune Modulation of Type I Diabetes***

**Jin-Xiong She, PhD;** Professor & Director of the Center for Biotechnology & Genomic Medicine, GRA Eminent Scholar in Genomic Medicine, Medical College of Georgia

#### ***Product Diversification Within a Core Technology***

**Albert E. Heacox, PhD;** Senior Vice President Research and Development, CryoLife, Inc.

#### ***Commercial Opportunities Using Human Embryonic Stem Cells in Drug Discovery***

**Steven L. Stice, PhD;** Professor, GRA Eminent Scholar and Director of the Regenerative Bioscience Center at University of Georgia and CSO, Aruna Biomedical Inc.

#### ***Biomedical Nanotechnology for Molecular Imaging, Profiling, and Drug Targeting***

**Shuming Nie, PhD;** Professor, Biomedical Engineering, Emory University and Georgia Institute of Technology; Wallace H. Coulter Distinguished Chair Professor

#### ***Found in Translation: Novel Therapies in Cardiovascular Medicine***

**Keith A. Robinson, PhD;** Principal Scientist, The American Cardiovascular Research Institute (ACRI)

---

**Joseph M. Patti, MSPH, PhD - Moderator;** Vice President Preclinical Development, Chief Scientific Officer and Member of the Board of Directors, Inhibitex, Inc.

### **2. POSTER SESSION**

### **3. POSTER DISCUSSION PRESENTATIONS**